We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

106 hedge funds and large institutions have $269M invested in VistaGen Therapeutics in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

2% more funds holding

Funds holding: 104 → 106 (+2)

0.03% more ownership

Funds ownership: 2.27% → 2.31% (+0.03%)

25% less capital invested

Capital invested by funds: $360M → $269M (-$91.2M)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

93% less call options, than puts

Call options by funds: $73K | Put options by funds: $1.04M

Holders
106
Holders Change
+2
Holders Change %
+1.92%
% of All Funds
1.63%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
13
Increased
39
Reduced
29
Closed
11
Calls
$73K
Puts
$1.04M
Net Calls
-$966K
Net Calls Change
-$312K

Top Buyers

1
CC
Commodore Capital
New York
+$7.25M
2
LGM
Logos Global Management
California
+$4.34M
3
NIP
Nicholas Investment Partners
California
+$3.26M
4
State Street
State Street
Massachusetts
+$1.62M
5
Bank of America
Bank of America
North Carolina
+$1.16M

Top Sellers

1
EI
EAM Investors
California
-$2.31M
2
Victory Capital Management
Victory Capital Management
Texas
-$2.18M
3
EGI
EAM Global Investors
California
-$1.74M
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.4M
5
Millennium Management
Millennium Management
New York
-$943K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$31.8M – – –
VA
2
VR Adviser
New York
$31.3M – – –
O
3
OrbiMed
New York
$25.2M – – –
BlackRock
4
BlackRock
New York
$23.2M +$316K +4,857 +1%
ACP
5
Acuta Capital Partners
California
$22.9M +$17.9K +275 +0.1%
Franklin Resources
6
Franklin Resources
California
$19.7M -$911 -14 -0%
Vanguard Group
7
Vanguard Group
Pennsylvania
$18.1M +$1.04M +15,911 +5%
State Street
8
State Street
Massachusetts
$16.8M +$1.62M +24,836 +9%
CC
9
Commodore Capital
New York
$16.5M +$7.25M +111,383 +65%
NIP
10
Nicholas Investment Partners
California
$8.36M +$3.26M +50,058 +54%
SFM
11
Sphera Funds Management
Israel
$7.85M +$434K +6,667 +5%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$5.99M -$12.8K -196 -0.2%
GTC
13
Ghost Tree Capital
New York
$3.9M – – –
LGM
14
Logos Global Management
California
$3.9M +$4.34M +66,667 New
Northern Trust
15
Northern Trust
Illinois
$3.81M -$93.6K -1,438 -2%
Goldman Sachs
16
Goldman Sachs
New York
$2.32M -$939K -14,427 -27%
EP
17
EPIQ Partners
Minnesota
$1.96M +$187K +2,875 +9%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$1.95M -$240K -3,690 -10%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$1.58M +$477K +7,327 +37%
HS
20
HighVista Strategies
Massachusetts
$1.13M +$301K +4,626 +32%
N
21
Nuveen
North Carolina
$1.05M -$127K -1,944 -9%
Bank of America
22
Bank of America
North Carolina
$1.04M +$1.16M +17,816 +63,629%
Rafferty Asset Management
23
Rafferty Asset Management
New York
$956K +$528K +8,120 +99%
SB
24
Samsara BioCapital
California
$953K – – –
Charles Schwab
25
Charles Schwab
California
$947K +$716 +11 +0.1%
1
2 3 4 5

VTGN Hedge Fund Activity: Q4 2021 in Review

106 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2021, worth a combined $269M — down 25% from $360M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new VTGN positions and 11 closed out — a net gain of 2 holders — while 39 added to existing stakes and 29 trimmed.

The largest buyer was Commodore Capital, adding an estimated $7.25M. The largest seller was EAM Investors, exiting entirely with an estimated $2.31M sold.

  • 106 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2021, up from 104 in Q3 2021.
  • Funds reported $269M of VistaGen Therapeutics stock for Q4 2021, down 25% quarter-over-quarter.
  • 13 funds opened new VistaGen Therapeutics positions in Q4 2021 and 11 closed out, a net change of +2 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2021 was Commodore Capital, an estimated $7.25M added.
  • The largest VistaGen Therapeutics seller in Q4 2021 was EAM Investors, an estimated $2.31M sold.

Based on aggregated 13F filings for Q4 2021.